DSIP (delta sleep inducing peptide or delta sleep peptide) was first discovered in 1974 by the Swiss G. Schoeneberger and M. Monnier, who isolated it from the brain blood of sleeping rabbits. Since the discovery, several hundred articles have been published, most of which describe the localization and involvement of the peptide in the brain and peripheral nervous system. 

The main property of DSIP is the ability to induce a stage of non-REM sleep, which is effective in combating insomnia. The peptide was found to affect electrophysiological activity, neurotransmitter levels in the brain, circadian and locomotor structures, hormonal levels, psychological performance and concentration, and the activity of neuropharmacological drugs.

A pronounced effect on withdrawal symptoms, including pain conditions in alcoholics and drug addicts, was noted. It has also been shown to be effective in chronic pain, including migraines.